Versant Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Versant Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.64K	Buy	22 +3	+16%	+$210	﹤0.01%	2584
2026 Q1	$1.41K	Buy	+19	New	+$1.38K	﹤0.01%	2613
2025 Q4	–	Sell	-27	Closed	-$1.4K	–	2654
2025 Q3	$1.4K	Sell	27 -11	-29%	-$536	﹤0.01%	2468
2025 Q2	$1.64K	Hold	38	–	–	﹤0.01%	2417
2025 Q1	$1.31K	Hold	38	–	–	﹤0.01%	2323
2024 Q4	$1.04K	Hold	38	–	–	﹤0.01%	2186
2024 Q3	$967	Sell	38 -102	-73%	-$2.68K	﹤0.01%	1751
2024 Q2	$3.55K	Buy	140 +102	+268%	+$2.79K	﹤0.01%	1334
2024 Q1	$1.18K	Hold	38	–	–	﹤0.01%	1500
2023 Q4	$1.53K	Hold	38	–	–	﹤0.01%	1384
2023 Q3	$1K	Hold	38	–	–	﹤0.01%	1526
2023 Q2	$654	Buy	+38	New	+$572	﹤0.01%	1742

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Versant Capital Management's BBIO Position: Q2 2026 in Review

Versant Capital Management increased its BridgeBio Pharma (BBIO) stake by 16% in Q2 2026, buying an estimated $210 and bringing the position to 22 shares worth $1.64K. The position accounts for ﹤0.01% of the portfolio, ranked #2584.

Versant Capital Management first reported a position in BBIO in Q2 2023 and has held it in 12 quarters since. The position peaked at $3.55K in Q2 2024. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Versant Capital Management held 22 shares of BridgeBio Pharma worth $1.64K as of Q2 2026.
Versant Capital Management bought 3 BridgeBio Pharma shares in Q2 2026, an estimated $210.
BridgeBio Pharma made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2584 holding.
Versant Capital Management first reported a position in BridgeBio Pharma in Q2 2023 and has held it in 12 quarters since.
Versant Capital Management's BridgeBio Pharma position peaked at $3.55K in Q2 2024.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.